Good morning, ladies and gentlemen. If we can all take our places so we could get started, I would really appreciate it. It is about seven minutes after 11 o'clock. I was a few minutes late because I was speaking in the House, so my apologies.
Having said that, I am pleased to announce that pursuant to Standing Order 108(2) and the motion adopted on Tuesday, December 11, 2007, the committee is beginning its study on post-market surveillance of pharmaceutical products, prescription and non-prescription.
I would like to welcome the officials from Health Canada who are here with us today. Welcome. We're so glad you could join us.
I would ask the assistant deputy minister, Ms. Meena Ballantyne, to introduce her colleagues before she begins her presentation.